Table 3.
Demographic and clinical differences at diagnosis and 8 years between patients without erosions (never erosive) and patients with erosions occasionally or consistently (ever erosive)
| At diagnosis | At 8 years | |||||
|---|---|---|---|---|---|---|
| Never erosive mean (SD) | Ever erosive mean (SD) | p value | Never erosive mean (SD) | Ever erosive mean (SD) | p value | |
| N (%) | 138 (25) | 407 (75) | 138 (25) | 407 (75) | ||
| Age, year | 52 (14.5) | 55 (13.2) | 0.014 | |||
| Gender, female, % | 67 | 71 | 0.337 | |||
| RF, % | 44 | 69 | < 0.001 | |||
| AntiCCP, % | 29 | 63 | < 0.001 | |||
| Seropos, % | 53 | 74 | < 0.001 | |||
| Never smoker, % | 45 | 43 | ||||
| Smoker, % | 21 | 28 | 0.212 | |||
| Prev. smoker, % | 34 | 29 | ||||
| Duration, months | 6 (3.2) | 6 (3.0) | 0.211 | |||
| DAS28 | 4.92 (1.37) | 5.01 (1.27) | 0.468 | 2.86 (1.32) | 2.91 (1.26) | 0.739 |
| PhAss | ||||||
| No, % | 3 | 1 | 50 | 42 | ||
| Low, % | 24 | 23 | 0.386 | 43 | 46 | 0.354 |
| Moderate, % | 58 | 58 | 7 | 10 | ||
| High, % | 15 | 18 | 1 | 2 | ||
| SJC | 9 (5.6) | 9 (5.8) | 0.228 | 1 (2.7) | 2 (3.2) | 0.010 |
| TJC | 8 (6.9) | 7 (5.8) | 0.031 | 3 (4.6) | 2 (3.4) | 0.013 |
| PatGA | 45 (26.4) | 45 (25.7) | 0.836 | 30 (25.9) | 29 (25.0) | 0.804 |
| ESR | 26 (20.8) | 32 (23.0) | 0.004 | 14 (15.1) | 18 (15.1) | 0.039 |
| CRP | 23 (27.6) | 31 (35.2) | 0.013 | 6 (6.4) | 9 (18.7) | 0.102 |
| Pain | 45 (25.2) | 46 (24.6) | 0.522 | 30 (25.0) | 30 (24.0) | 0.659 |
| HAQ | 0.90 (0.66) | 0.91 (0.59) | 0.929 | 0.59 (0.55) | 0.57 (0.59) | 0.695 |
| ES | 0 | 2 (3.9) | < 0.001 | 0 | 10 (10.5) | < 0.001 |
| JSN | 0 (1.6) | 5 (7.9) | < 0.001 | 3 (5.2) | 22 (18.2) | < 0.001 |
| SHS | 0 (1.5) | 7 (10.5) | < 0.001 | 3 (5.2) | 32 (26.1) | < 0.001 |
| Treatment | ||||||
| No DMARD, % (Std.Res.) | 26 (1.7) | 18 (− 1.0) | 34 (2.8) | 19 (− 1.6) | ||
| cDMARD, % (Std.Res.) | 57 (− 1.5) | 71 (0.9) | 0.008 | 53 (− 1.2) | 63 (0.7) | < 0.001 |
| bDMARD, % (Std.Res.) | 0 | 0 | 5 (− 2.1) | 13 (1.3) | ||
| CS no DMARD, % (Std.Res.) | 17 (1.5) | 11 (− 0.9) | 8 (1.3) | 5 (− 0.8) | ||
RF rheumatoid factor, AntiCCP anticyclic citrullinated peptides, Seropos. RF and/or antiCCP positive, DAS28 disease activity score of 28 joints, PhAss physician´s global assessment of disease activity, SJC swollen joint count, TJC tender joint count, PatGA patient global assessment, ESR erythrocyte sedimentation rate, CRP C-reactive protein, HAQ health assessment questioner, ES erosion score, JSN joint space narrowing, SHS Sharp van der Heijde score, DMARD disease modifying antirheumatic drugs, c conventional, b biological, CS corticosteroids